INS and type 2 diabetes mellitus: His outcomes paralleled trajectories seen in the active treatment arms of SURPASS-5, in which patients with T2DM on insulin achieved mean weight reductions of 5–9 % and HbA1c reductions of 1.2–2.3 points by 40 weeks (Fig. 1) [3].